Article Versions Notes

Atay A, Cagir Y, Ergul M, Ozturk O, Durak MB, Yuksel I. Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment. Journal of Clinical Medicine. 2025; 14(4):1228. https://doi.org/10.3390/jcm14041228

Atay, Ali, Yavuz Cagir, Mucahit Ergul, Oguz Ozturk, Muhammed Bahaddin Durak, and Ilhami Yuksel. 2025. "Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment" Journal of Clinical Medicine 14, no. 4: 1228. https://doi.org/10.3390/jcm14041228

Atay, A., Cagir, Y., Ergul, M., Ozturk, O., Durak, M. B., & Yuksel, I. (2025). Comparative Outcomes of Adalimumab and Infliximab Dose Escalation in Inflammatory Bowel Disease Patients Failing First-Line Biologic Treatment. Journal of Clinical Medicine, 14(4), 1228. https://doi.org/10.3390/jcm14041228